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University of Chicago Medical Center, Chicago, IL, USA, 2 Hôpital Beaujon, Clichy, France, 3 F. Hoffmann La Roche Ltd., Basel, Switzerland, 4 Roche Products Ltd., Welwyn Garden City, UK OBJECTIVES: Standard treatment for hepatitis C is peginterferon (PEG-IFN) RBV with the aim of achieving a sustained-virological-response (SVR), which is widely considered to be a cure. Around 50% of patients infected with G1 do not achieve an SVR but re-treatment with PEG-IFN RBV is successful in some, especially in those who achieve a complete-early-virological-response (HCV-RNA undetectable by week 12 [cEVR] ). The objective of this analysis was to determine the cost-effectiveness of re-treating previous G1-non-responders to PEG-IFN RBV. METHODS: A published Markov-model compared three strategies: PEG-IFN 2a RBV, for 72 weeks (A), 48 weeks (B) or no treatment (C). Efficacy data for (A) and (B) were taken from the REPEAT study, where a difficult-to-treat population of G1-patients with previous non-response to PEG-IFN/RBV was investigated. Rates of cEVR were 15% for (A) and 9% for (B); SVR rates: 13% for (A) and 7% for (B); rates for (C) assumed to be zero. Patients not achieving a cEVR were assumed to discontinue treatment. A UK health care payor perspective was adopted. Drug and other costs were taken from published sources. A lifetime-horizon was chosen. Incremental-cost-effectivenessratios were expressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs were discounted at 3.5% p.a. Sensitivity-analyses were performed. RESULTS: The analysis showed that an additional SVR prevented future costs and increased quality-adjusted-life-expectancy. Although (A) caused the highest overall drug costs, total costs were only £606 higher compared to (B) and £1949 compared to (C), reflecting the higher SVR rates and the substantial medical costs for patients without an SVR. The ICER of (A) vs. (B) was estimated at £2,012/QALY and £2,988/QALY for (A) vs. (C). CONCLUSIONS: Re-treatment with PEG-IFN 2a RBV for 72 weeks is a highly cost-effective treatment option for patients not responding to previous treatment with PEG-IFN RBV, regardless of comparator, due to reduction of the high medical costs associated with progressive liver disease and the associated QALY gains.
PIN54 THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
Patel R 1 , Stoykova B 2 , Lloyd AC 1 , Willingham J 2 , Hollingsworth R 2 1 IMS Health, London, UK, 2 Wyeth, Maidenhead, Berkshire, UK OBJECTIVES: The 7-valent pneumococcal conjugate vaccine (PCV7) and 23-valent pneumococcal polysaccharide vaccine (PPV23) are currently recommended for childhood and adult vaccination respectively in the UK. A 13-valent pneumococcal conjugate vaccine (PCV13) is currently being reviewed by regulatory authorities for use in infants and young children, and a clinical development plan for adults is ongoing. This study assessed cost-effectiveness of PCV13 compared to the current vaccination strategy and to PCV7 given to children alone. METHODS: A steady state, static cohort model was constructed comparing PCV13 vaccination of the birth cohort and of 65-year old adults with the current strategy and with PCV7 in children alone. The model con sidered the incidence and subsequent costs of four infections: pneumococcal meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media (AOM). Vaccination was assumed to have effects on vaccinated individuals and to impact unvaccinated individuals as a result of herd immunity. The number of cases and subsequent costs that would occur were estimated in the different scenarios. Sensitivity analysis considered incidence, mortality rates, vaccine efficacy, serotype cover, costs, discount rate, uptake and herd immunity. RESULTS: The model estimated that, compared to the current strategy (and compared to PCV7 alone), PCV13 would reduce the annual incidence of bacteraemia and meningitis by 1176 (1303) cases, prevent 35 (40) deaths, increase life years by 619 (666), increase QALYs by 694 (731) and reduce medical costs by £2.9m (£11.1m). Results are sensitive to vaccine effects against pneumonia and the disease incidence in non-vaccinated individuals. CONCLUSIONS: Paediatric and adult PCV13 vaccination in the UK was estimated to reduce the burden of pneumococcal disease and save costs compared with either the current vaccination strategy or a paediatric PCV7 only strategy. Final cost-effectiveness will depend on the emergence of herd immunity benefits in the UK, impact on pneumonia, vaccine schedule and price. Observational prospective before and after study in 59 medical-surgical intensive care units located throughout Spain. A total of 854 patients were enrolled in the pre-educational program cohort (usual or standard care usual or standard care of severe sepsis, November-December 2005) and 1465 patients during the post-) and 1465 patients during the posteducational program (SSC protocol care of severe sepsis, March-June 2006). The educational program aimed to increase the adherence to the SSC protocol. The SSC protocol included pharmacological (antibiotics, fluids, steroids and drotrecogina alfa (activated)) and medical (early-goal directed therapy, tight glucose control and lung protective strategy) interventions. Clinical (hospital mortality) and economical (health care resource and treatment costs) outcomes were recorded. Health care system perspective was used for costs. Incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios (ICURs) were used as primary outcomes. ICERs and ICURs were estimated by using multivariable regression models and its variability addressed by using bootstrapping. RESULTS: Patients in the SSC protocol care cohort Patients in the SSC protocol care cohort had a lower risk of hospital mortality (44.0% vs. 39.7%, P 0.04). However, the SSC protocol care resulted in a mean increase in cost of a1800 per patient, largely driven by increased length of stay. Mean life years gained (LYG) and quality-adjusted life years (QALYs) were higher in the SSC protocol care cohort: 0.7 years and 0.5 QALYs, respectively. The adjusted ICER of the SSC protocol was a2556.9 per LYG and the adjusted ICUR was a3579.6 per QALY. Ninety percent of the bootstrap replications were below the threshold of a30,000 per LYG. CONCLUSIONS: The The SSC protocol seems to be a cost-effectiveness option for treating severe sepsis in Spain.
PIN55 COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN

PIN56 COST-EFFECTIVENESS OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT NAIVE HIV PATIENTS IN SPAIN
Thuresson PO 1 , Heeg B 1 , Serrano O 2 , Ramirez de Arellano A 2 1 PharMerit Europe, Rotterdam, The Netherlands, 2 Bristol-Myers Squibb Iberia, Madrid, Spain OBJECTIVES: To assess the cost-effectiveness of atazanavir/r vs. lopinavir/r in treatment-naïve HIV patients in Spain. METHODS: A life-time Markov-cohort model was created with the following health states 1 st line, 2 nd line and salvage therapy. The cycle length was one year; patients could switch treatment due to adverse events, lack of efficacy or non-compliance. Those discontinuing 1 st line treatment due lack of efficacy switched to darunavir/r. Those that discontinued 1 st line due to adverse events or non-compliance switched to efavirenz/emtricitabine/tenofovir. Everyone discontinuing 2 nd line was given a salvage therapy. Patients were at risk of developing a cardiovascular event or to die in each state. Drug specific safety and efficacy inputs were taken from the 48 week CASTLE trial, risk of cardiovascular events were estimated with Framingham equation and risk of death was from Spanish life-tables and literature. The analysis was done from a societal perspective; outcomes were total costs and Quality-Adjusted Life Years after life-time. Robustness was assessed by uni-and multivariate sensitivity analyses. Recent 96-week trial efficacy and safety data from the CASTLE was used as a scenario analysis. RESULTS: The model forecasted a difference of 0.20 [0.11 to 0.32] QALYs after life-time and a reduction in total costs of a7,000 [ a28,888 to a12,491]. Probabilistic sensitivity analyses showed that atazanavir/r has a 23.5% and a 76.5% probability to be in the NE and SE quadrant of cost-effectiveness plane. Univariate sensitivity analysis showed that results were most sensitive to changes in probabilities of switching treatment. In the scenario analysis, a QALY gain of 0.21 was estimated and total costs were estimated to be a4500 higher for atazanavir/r. CONCLUSIONS: This analysis suggests that atazanavir/r has a favorable cost-effectiveness ratio for treatment naïve HIV patients in Spain.
PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
Patel R 1 , Stoykova B 2 , Lloyd AC 1 , Willingham J 2 , Hollingsworth R 2 1 IMS Health, London, UK, 2 Wyeth, Maidenhead, Berkshire, UK OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7, Prevenar*) is currently recommended for childhood vaccination in the UK. A 10-valent vaccine (PCV10, Synflorix, GSK) is licensed and a 13-valent vaccine (PCV13, Wyeth) is currently being reviewed by regulatory authorities. This study estimated the cost effectiveness of PCV13 and PCV10 compared to PCV7 for childhood vaccination in the UK. METHODS: A steady state, static cohort model was constructed comparing the incremental benefit of PCV13 compared to PCV7 and PCV10 compared to PCV7 for vaccination of the entire birth cohort. In children, the model considered the incidence and subsequent costs of four disease states: pneumococcal meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media (AOM). In adults the model considered invasive pneumococcal disease (IPD) and all cause pneumonia, exploring the potential impact of herd immunity. Sensitivity analyses were conducted on incidence, mortality rates, vaccine efficacy, serotype coverage and costs, discount rate, uptake and non-vaccine serotype prevalence. RESULTS: The model estimated that, in addition to PCV7, PCV13 (PCV10) would annually reduce the incidence of IPD by 888 (573) cases, prevent 23 (16) deaths, increase the number of life years gained by 509 (343), increase QALYs gained by 611 (375) and reduce medical costs by £5.2m (£3.3m). The benefits of the new vaccines are sensitive to efficacy and the magnitude and pattern of herd immunity that emerges. CONCLUSIONS: Our analysis found that PCV13 vaccination in the UK will be more effective than PCV10 in reducing the burden of pneumococcal disease when compared to PCV7 and will further reduce cost. Final cost-effectiveness will depend on the emergence of herd immunity benefits in the UK, the impact on AOM and pneumonia, the vaccination schedule deployed and price of PCV13 and PCV10.
PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-1-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS
Moeremans K 1 , Hjelmgren J 2 , Martin SC 3 1 IMS HEOR, Brussels, Belgium, 2 Janssen-Cilag AB, Sollentuna, Sweden, 3 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium OBJECTIVES: To determine whether, from the Swedish health care payer perspective etravirine is cost-effective when added to a standard highly active antiretroviral treatment (HAART) in multi-drug resistant HIV-1 infected adults. METHODS: Etravirine added to a standard regimen including darunavir/r, an optimized background regimen (OBR) of nucleoside reverse transcriptase inhibitors (NRTIs) and optionally enfuvirtide was compared to the same standard regimen alone. The target population consisted of HIV-1-infected pretreated patients with resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and 3 protease inhibitor (PI) mutations. Cost-effectiveness, expressed as cost per quality-adjusted life year (QALY) gained, was calculated using a lifetime Markov model. The model predicted patient flow through six health states representing CD4 T-cell count ranges ( 500, 351-500, 201-350, 101-200 , 51-100 and 0-50 cells/mm3), and one absorbing 'death' state. After treatAfter treatment failure, a switch to a raltegravir regimen was assumed. Transition probabilities raltegravir regimen was assumed. Transition probabilities . Transition probabilities probabilities describing patient flow through the model were obtained from immunologic response rates per virologic response category observed in the DUET trials for etravirine and placebo and reported in phase III trials for raltegravir. All-cause mortality was All-cause mortality was obtained from Swedish statistics. HIV-related mortality, utilities and non-ARV costs associated with each CD4 T-cell count range were obtained from literature. AntiretAntiretroviral (ARV) drug use reflected that observed in the clinical trials. Outcomes and ARV) drug use reflected that observed in the clinical trials. Outcomes and and costs expressed in 2008 Swedish Kronor (SEK) were discounted at 3%. The impact of parameter uncertainty was explored in one-way as well as probabilistic sensitivity analysis. Variability analyses explored different model assumptions. RESULTS: The analysis predicted a gain in discounted QALYs of 0.461 and an incremental cost per QALY of SEK362,583, ranging from 240,074SEK/QALY to 474,935SEK/QALY in sensitivity and variability analyses. CONCLUSIONS: The results suggest etravirine to be cost-effective in Sweden when added to a standard multi-drug regimen in pretreated HIV patients with evidence of NNRTI and PI resistance.
PIN59 POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG-A DECISION ANALYSIS
You JH, So M, So Y, Ip M, Lee NL The Chinese University of Hong Kong, Shatin, N.T, Hong Kong OBJECTIVES: Outpatient parenteral antimicrobial therapy (OPAT) with carbapenem for bacteraemia caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria may potentially be cost-saving. Yet in Hong Kong, China and many southeast Asia regions, patients requiring intravenous antimicrobial therapy are usually treated in an in-patient setting. In the present study, we analyzed the cost of inpatient versus outpatient carbapenem treatment for ESBL bacteraemia. METHODS: Economic outcomes of two antimicrobial strategies were simulated by a decision tree: 1) inpatient carbapenem treatment; 2) outpatient group (initially inpatient carbapenem treatment followed by ertapenem OPAT). Clinical inputs were estimated from literature and cost analysis was conducted from Hong Kong public health care provider's perspective. Robustness of model was examined by sensitivity analysis. RESULTS: The results showed that outpatient group (US$12,008) was less costly than the inpatient group (US$15,446) (USD1 HKD7.8) by 22% in base-case analysis. The model was robust to variation of all variables in one-way sensitivity analysis. In Monte Carlo stimulations, cost of outpatient group (US$13,153 2,064) was significantly lower than the 2,064) was significantly lower than the inpatient group (US$15,650 1,602) 98.6% of the time by a mean difference of 1,602) 98.6% of the time by a mean difference of US$2,497 (95% CI US$2,469-2,525) (p 0.0001). CONCLUSIONS: Initial inpatient carbapenem treatment followed by OPAT appears to be less costly than an inpatient treatment course for ESBL bacteraemia from the perspective of Hong Kong public health care providers. 
